[1] |
Tang PT, Shenasa M, Boyle NG. Ventricular arrhythmias and sudden cardiac death[J]. Card Electrophysiol Clin, 2017, 9(4):693-708.
|
[2] |
Roger VL. Epidemiology of Heart Failure: A Contemporary Perspective. Circ Res[J]. 2021, 128(10):1421-1434.
|
[3] |
陈伟伟, 高润霖, 刘力生,等. «中国心血管病报告2017»概要[J].中国循环杂志, 2018, 33(1):1-8.
|
[4] |
Hao G, Wang X, Chen Z, et al. China Hypertension Survey Investigators. Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015[J]. Eur J Heart Fail, 2019, 21(11):1329-1337.
|
[5] |
Szabó BM, van Veldhuisen DJ, Crijns HJ, et al. Value of ambulatory electrocardiographic monitoring to identify increased risk of sudden death in patients with left ventricular dysfunction and heart failure[J]. Eur Heart J, 1994, 15(7):928-933.
|
[6] |
Cho JH, Leong D, Cuk N,et al. Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction[J]. PLoS One, 2021, 16(7):e0254641.
|
[7] |
Skogestad J, Aronsen JM. Hypokalemia-induced arrhythmias and heart failure: new insights and implications for therapy[J]. Front Physiol, 2018, 9:1500.
|
[8] |
Wang Y, Hill JA. Electrophysiological remodeling in heart failure[J]. J Mol Cell Cardiol, 2010, 48(4):619-632.
|
[9] |
Tamariz L, Goldberger JJ, Palacio A, et al. The additive role of echocardiography in the screening for sudden death[J]. Echocardiography, 2019 , 36(3):451-457.
|
[10] |
Zaman S, Goldberger JJ, Kovoor P. Sudden death risk-stratification in 2018-2019: The old and the new[J]. Heart Lung Circ, 2019, 28(1):57-64.
|
[11] |
Narayanan K, Reinier K, Teodorescu C, et al. Left ventricular diameter and risk stratification for sudden cardiac death[J]. J Am Heart Assoc, 2014, 3(5):e001193.
|
[12] |
Centurión OA, Alderete JF, Torales JM,et al. Myocardial fibrosis as a pathway of prediction of ventricular arrhythmias and sudden cardiac death in patients with nonischemic dilated cardiomyopathy[J]. Crit Pathw Cardiol, 2019, 18(2):89-97.
|
[13] |
Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J, 2022:ehac262.
|
[14] |
Kanitsoraphan C, Rattanawong P, Mekraksakit P, et al. Baseline fragmented QRS is associated with increased all-cause mortality in heart failure with reduced ejection fraction: A systematic review and meta-analysis[J]. Ann Noninvasive Electrocardiol, 2019, 24(2):e12597.
|
[15] |
Zile MA, Trayanova NA. Rate-dependent force, intracellular calcium, and action potential voltage alternans are modulated by sarcomere length and heart failure induced-remodeling of thin filament regulation in human heart failure: a myocyte modeling study[J]. Prog Biophys Mol Biol, 2016, 120(1-3):270-280.
|
[16] |
Vrtovec B, Knezevic I, Poglajen G, et al. Relation of B-type natriuretic peptide level in heart failure to sudden cardiac death in patients with and without QT interval prolongation[J]. Am J Cardiol, 2013, 111(6):886-890.
|
[17] |
Sessa F, Anna V, Messina G, et al. Heart rate variability as predictive factor for sudden cardiac death[J]. Aging (Albany NY), 2018 , 10(2):166-177.
|
[18] |
Kiuchi MG, Nolde JM, Villacorta H, et al. New approaches in the management of sudden cardiac death in patients with heart failure-targeting the sympathetic nervous system[J]. Int J Mol Sci, 2019, 20(10):2430.
|
[19] |
唐继志, 李忠杰, 方永生,等. 心衰患者自主神经功能与临床相关因素的研究[J].中华心血管病杂志, 2004(3):52-53.
|
[20] |
Zakrzewska-Koperska J, Franaszczyk M, Bilińska Z,et al. Rapid and effective response of the R222Q SCN5A to quinidine treatment in a patient with Purkinje- related ventricular arrhythmia and familial dilated cardiomyopathy: a case report[J].BMC Med Genet, 2018, 19( 1) : 94.
|
[21] |
Osman J, Tan SC, Lee PY, et al. Sudden cardiac death (SCD) - risk stratification and prediction with molecular biomarkers[J]. J Biomed Sci, 2019, 26(1):39.
|
[22] |
Zhang ZH, Barajas-Martínez H, Xia H, et al. Distinct features of probands with early repolarization and brugada syndromes carrying SCN5A pathogenic variants[J]. J Am Coll Cardiol, 2021, 78(16):1603-1617.
|
[23] |
Vaksmann G, Klug D. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia[J]. Pacing Clin Electrophysiol, 2018 , 41(10):1378-1380.
|
[24] |
Schupp T, Behnes M, Kim SH,et al. Comparable risk of recurrent ventricular tachyarrhythmias in implantable cardioverter-defibrillator recipients treated with single beta-blocker or combined amiodarone[J]. Basic Clin Pharmacol Toxicol, 2021, 128(3):493-502.
|
[25] |
Mujović N, Dobrev D, Marinković M, et al. The role of amiodarone in contemporary management of complex cardiac arrhythmias[J]. Pharmacol Res, 2020, 151:104521.
|
[26] |
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the american college of Cardiology/American heart association task force on clinical practice guidelines and the heart failure society of america[J]. Circulation, 2017, 136(6):e137-e161.
|
[27] |
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines[J]. Circulation, 2022, 145(18):e895-e1032.
|
[28] |
Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22):2117-2128.
|
[29] |
Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials[J]. Heart Rhythm, 2021, 18(7):1098-1105.
|
[30] |
Goldenberg I, Huang DT, Nielsen JC. The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome[J]. Eur Heart J, 2020 , 41(21):2003-2011.
|
[31] |
中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会. 植入型心律转复除颤器临床应用中国专家共识(2021)[J].中华心律失常学杂志, 2021, 25(4):280-299.
|
[32] |
Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. PRAETORIAN Investigators. Subcutane ous or transvenous defibrillator therapy[J]. N Engl J Med, 2020, 383(6):526-536.
|
[33] |
McDonagh TA, Metra M, Adamo M,et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36):3599-3726.
|
[34] |
Yalin K, Liosis S, Palade E, et al. Cardiac sympathetic denervation in patients with nonischemic cardiomyopathy and refractory ventricular arrhythmias: a single-center experience[J]. Clin Res Cardiol, 2021 , 110(1):21-28.
|
[35] |
Kiuchi MG, Nolde JM, Villacorta H, et al. New approaches in the management of sudden cardiac death in patients with heart failure-targeting the sympathetic nervous system[J]. Int J Mol Sci, 2019, 20(10):2430.
|